| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,681,140 | 2 | 12 |
Sells | $21,969,163 | 15 | 88 |
| MORTIMER IAN | PRESIDENT & CEO | 1 | $1.12M | 7 | $20.29M | $-19.17M |
| Kelly Thomas Patrick | Chief Financial Officer | 1 | $559,740 | 0 | $0 | $559,740 |
| Cannon Gillian | director | 0 | $0 | 1 | $63,237 | $-63,237 |
| PATOU GARY | director | 0 | $0 | 1 | $70,251 | $-70,251 |
| DiFabio Andrea | Chief Legal Officer | 0 | $0 | 2 | $230,814 | $-230,814 |
| GANNON STEVEN | director | 0 | $0 | 1 | $640,550 | $-640,550 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 0 | $0 | 3 | $670,256 | $-670,256 |
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase …
Over the last 12 months, insiders at Xenon Pharmaceuticals Inc. have bought $1.68M and sold $21.97M worth of Xenon Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Xenon Pharmaceuticals Inc. have bought $958,337 and sold $8.99M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MORTIMER IAN (PRESIDENT & CEO) — $1.12M. Kelly Thomas Patrick (Chief Financial Officer) — $559,740.
The last purchase of 30,000 shares for transaction amount of $1.12M was made by MORTIMER IAN (PRESIDENT & CEO) on 2026‑09‑30.
| 2026-09-30 | MORTIMER IAN | PRESIDENT & CEO | 30,000 0.0312% | $37.38 | $1.12M | -2.38% | ||
| 2026-09-30 | Kelly Thomas Patrick | Chief Financial Officer | 15,000 0.0156% | $37.32 | $559,740 | -2.38% | ||
| 2026-08-28 | Sale | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 7,068 0.0071% | $60.25 | $425,829 | -37.53% | |
| 2026-08-11 | Sale | GANNON STEVEN | director | 10,000 0.0105% | $64.06 | $640,550 | -38.42% | |
| 2026-06-05 | Sale | PATOU GARY | director | 1,322 0.0017% | $53.14 | $70,251 | +13.84% | |
| 2026-06-05 | Sale | Cannon Gillian | director | 1,190 0.0015% | $53.14 | $63,237 | +13.84% | |
| 2026-03-13 | Sale | MORTIMER IAN | PRESIDENT & CEO | 7,308 0.0088% | $55.23 | $403,584 | +1.43% | |
| 2026-03-13 | Sale | DiFabio Andrea | Chief Legal Officer | 1,342 0.0016% | $55.23 | $74,112 | +1.43% | |
| 2026-03-13 | Sale | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 1,410 0.0017% | $55.23 | $77,867 | +1.43% | |
| 2026-03-10 | Sale | MORTIMER IAN | PRESIDENT & CEO | 11,269 0.014% | $60.11 | $677,357 | -7.54% | |
| 2026-03-10 | Sale | DiFabio Andrea | Chief Legal Officer | 2,607 0.0032% | $60.11 | $156,702 | -7.54% | |
| 2026-03-10 | Sale | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 2,771 0.0034% | $60.11 | $166,559 | -7.54% | |
| 2026-03-09 | Sale | MORTIMER IAN | PRESIDENT & CEO | 270,000 0.5026% | $60.33 | $16.29M | -10.64% | |
| 2026-01-02 | Sale | MORTIMER IAN | PRESIDENT & CEO | 40,000 0.0513% | $44.43 | $1.78M | +22.96% | |
| 2025-12-08 | Sale | MORTIMER IAN | PRESIDENT & CEO | 10,830 0.0144% | $45.73 | $495,207 | +21.65% | |
| 2025-12-05 | Sale | MORTIMER IAN | PRESIDENT & CEO | 14,375 0.0186% | $45.03 | $647,306 | +20.30% | |
| 2025-11-28 | Sale | MORTIMER IAN | PRESIDENT & CEO | 97 0.0001% | $45.01 | $4,366 | +20.71% | |
| 2025-10-01 | Sale | MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | 25,000 0.0324% | $40.16 | $1M | +34.94% | |
| 2025-06-05 | Sale | GANNON STEVEN | director | 3 <0.0001% | $30.48 | $91 | +35.89% | |
| 2025-01-27 | Sale | MORTIMER IAN | PRESIDENT & CEO | 16,315 0.0216% | $40.50 | $660,806 | -5.71% |
| MORTIMER IAN | PRESIDENT & CEO | 49923 0.0516% | $1.91M | 3 | 12 | +28.18% |
| PATOU GARY | director | 24896 0.0257% | $951,774.08 | 2 | 5 | +22.11% |
| Kelly Thomas Patrick | Chief Financial Officer | 15000 0.0155% | $573,450.00 | 1 | 0 | |
| GANNON STEVEN | director | 1870 0.0019% | $71,490.10 | 1 | 3 | +31.48% |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 2 0% | $76.46 | 1 | 4 | +29.65% |
| BVF PARTNERS L P/IL | 10 percent owner | 1674468 1.7291% | $64.01M | 10 | 0 | <0.0001% |
| Hayden Michael R | director | 161187 0.1664% | $6.16M | 1 | 0 | +44.6% |
| AZAB MOHAMMAD | director | 57561 0.0594% | $2.2M | 5 | 1 | +72.32% |
| Svoronos Dawn | director | 25000 0.0258% | $955,750.00 | 1 | 1 | +44.6% |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 10000 0.0103% | $382,300.00 | 1 | 3 | +48.57% |
| SCHELLER RICHARD H | director | 7000 0.0072% | $267,610.00 | 1 | 0 | +28.18% |
| PIMSTONE SIMON N. | director | 6000 0.0062% | $229,380.00 | 1 | 12 | +28.18% |
| Von Seggern Christopher | Chief Commercial Officer | 4000 0.0041% | $152,920.00 | 1 | 0 | +29.4% |
| WINQUIST RAYMOND | Head, Translational Research | 1000 0.001% | $38,230.00 | 1 | 0 | +25.42% |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$151,136,640 | 31 | -1.41% | $3.95B | |
Xenon Pharmaceuticals Inc. (XENE) | $5,066,938 | 27 | 26.38% | $3.7B |
$137,434,288 | 25 | 37.98% | $4.02B |
| Increased Positions | 135 | +56.72% | 10M | +12.27% |
| Decreased Positions | 99 | -41.6% | 10M | -11.65% |
| New Positions | 52 | New | 3M | New |
| Sold Out Positions | 23 | Sold Out | 1M | Sold Out |
| Total Postitions | 274 | +15.13% | 85M | +0.62% |
| Fmr Llc | $396,802.00 | 11.58% | 8.92M | +34,544 | +0.39% | 2025-09-30 |
| Avoro Capital Advisors Llc | $240,246.00 | 7.01% | 5.4M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $212,260.00 | 6.2% | 4.77M | -594,376 | -11.08% | 2025-09-30 |
| Driehaus Capital Management Llc | $185,484.00 | 5.41% | 4.17M | -166,534 | -3.84% | 2025-09-30 |
| Janus Henderson Group Plc | $175,463.00 | 5.12% | 3.94M | +366,150 | +10.23% | 2025-09-30 |
| Wellington Management Group Llp | $160,603.00 | 4.69% | 3.61M | +1M | +65.99% | 2025-09-30 |
| Braidwell Lp | $160,388.00 | 4.68% | 3.61M | 0 | 0% | 2025-09-30 |
| Capital International Investors | $141,545.00 | 4.13% | 3.18M | -56 | <0.01% | 2025-09-30 |
| Commodore Capital Lp | $120,123.00 | 3.51% | 2.7M | -325,000 | -10.74% | 2025-09-30 |
| Polar Capital Holdings Plc | $113,306.00 | 3.31% | 2.55M | -156,490 | -5.79% | 2025-09-30 |